Néoplasie

Fr | De

Feedback | Impressum | Sitemap

Aucun choix d'articles!

Panier

Vous êtes ici: Recherche de documentation spécialisée » Œsophage » Néoplasie

09. Octobre 2026

Dépistage / diagnostic

Recherche de documentation spécialisée

Troubles de la motilité

Écriture:

Page 1 de 1991


	Articles 1 - 20 / 39818

	[Modern concepts in the surgical treatment of esophageal cancer]. Chirurgie (Heidelb) Schlößer HA, Schiffmann LM, Fuchs HF, Bruns CJ. PMID: 42848081 [PubMed - as supplied by publisher]
	Exploring Home Nutrition Management Experiences in Postoperative Esophageal Cancer Patients and Their Caregivers: A Study Utilizing Patient Journey Mapping. Patient Prefer Adherence Zhang L, Tang W, Yang S, Zhou L, Zhang W, Zhu J, Xie Y. PMID: 42846595 [PubMed]
	Effect of structured nursing care on treatment tolerance and quality of life in patients with esophageal cancer undergoing radiotherapy: a retrospective cohort study. Front Oncol Zhao C, Huang X, Han Y, Fu J, Zhang H. PMID: 42846280 [PubMed]
	Development of a risk-stratified follow-up strategy based on early and late recurrence risk factors in locally advanced esophageal squamous cell carcinoma after definitive chemoradiotherapy. Front Oncol Hong L, Qiu J, Ye Y, Yu Y, Wang Z, Chen M, Zhang W. PMID: 42846082 [PubMed]
	Risk factors for metachronous esophageal squamous cell carcinoma after endoscopic submucosal dissection: a multicenter cohort study integrating overall risk prediction and timing of recurrence. Front Med (Lausanne) Gui G, Yang L, Wang X, Liu R, Ma H, Yang M, Fan R, Wang Q, Sun B. PMID: 42845977 [PubMed]
	Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer. Cancer Zhu D, Fang Z, Jin G, Chen J, Lu Y, Yang T, Shen K, Shi Y, Zheng Y, Xu W, Cheng X, Wei Q. PMID: 42845003 [PubMed - indexed for MEDLINE]
	Serum soluble signal regulatory protein alpha as a potential prognostic biomarker after surgery for esophageal cancer. Clin Immunol Antonsen KW, Katballe N, Kjær DW, Christensen TD, Møller HJ, Gyldenholm T. PMID: 42843775 [PubMed - as supplied by publisher]
	Epigenetic and Epitranscriptomic Regulation of Immune Checkpoint Response in Hepatocellular Carcinoma: Mechanisms, Therapeutic Targeting, and Translational Challenges. Clin Mol Hepatol Zhi Y, Guo Y, Wei H, Gantier MP, Ma X, Dong Z, Liu K. PMID: 42843420 [PubMed - as supplied by publisher]
	Gastrointestinal symptom profiles after resection of esophageal or gastric cancer. Support Care Cancer Lee Y, Katsimpokis D, van Erning FN, Nieuwenhuijzen GAP, van Laarhoven HWM, Gisbertz SS, Klarenbeek BR, Jeene PM, Pouw RE, Noteboom L, Verhoeven RHA, Vissers PAJ. PMID: 42842001 [PubMed - indexed for MEDLINE]
	CLEVER-1(+) tumor-associated macrophages in gastric cancer immunotherapy resistance: integrating metabolic reprogramming and immunosuppression. Front Immunol Yuan H, Li N, Qiu H, Wang L, Li Y. PMID: 42840964 [PubMed - indexed for MEDLINE]
	Five-Year Survival Analyses on Non-Pathological Complete Response Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Regimens Plus Surgery: A Propensity Score Matching, Real-World Cohort Study. Cancer Med Liu W, Deng Y, Lin Y, Lin Y, Zheng X, Su W, Xiao W, Shi Y, Zhang J, Chen X. PMID: 42839363 [PubMed - indexed for MEDLINE]
	Sensitivity and Specificity of Chest CT for Detection of Esophageal Cancer. Acad Radiol Siddiqui TA, Kaproth-Joslin K, Proffitt EK, Baran TM, Shiau MC. PMID: 42838881 [PubMed - as supplied by publisher]
	Thoracic Surgery Oncology Quality Indicators (Part 2: Thymic Epithelial Tumors and Esophageal Cancer). Thorac Surg Clin Plourde M, Chen A, Brownstone R. PMID: 42838627 [PubMed - indexed for MEDLINE]
	Trends and Projections of Esophageal Cancer Incidence and Mortality in China, 1990 to 2050: An Analysis of the Global Burden of Disease Study 2023. J Clin Gastroenterol Su P, Xu Y, Wen S, Lv H, Zhu Y, Wang H, Tian Z. PMID: 42837608 [PubMed - as supplied by publisher]
	Impact of PD-1 and PD-L1 inhibitors on patient-reported outcomes in esophageal squamous cell carcinoma: a systematic review of clinical trials. Curr Med Res Opin Choi SA, Wong WJ, Barnes FB, Buck PO, Allaire JC. PMID: 42836832 [PubMed - as supplied by publisher]
	Optimal Sequencing of First-Line Immune Checkpoint Inhibitors With Definitive Chemoradiotherapy: A Multicenter Real-World Cohort Study Comparing Induction, Concurrent, and Consolidation Strategies for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma. Int J Cancer Zhao X, Wen S, Song C, Wang J, Zhang Y, Wang C, Liu Y, Qian P, Cao J, Hou Q, Xu Y, Lin Z, Ye X, Hou M, Gui Y, Wang L, Zhou W, Zeng Z, Song Y, Luo H, Lv J, Zhu S, Shen W. PMID: 42836385 [PubMed - as supplied by publisher]
	The Dual Role of Piezo1 in Cancer: Mechanotransduction, Microenvironment Remodelling, and Therapeutic Opportunities. Drug Des Devel Ther Jiang H, Liu Y, Xue F, Sun H, Ji Y, Qi L. PMID: 42836163 [PubMed - indexed for MEDLINE]
	First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306). Nat Commun Yoon HH, Kato K, Raymond E, Hubner R, Shu Y, Pan Y, Park SR, Kojima T, Lin CY, Wyrwicz L, Tougeron D, Ishihara R, Wang K, Peng Y, Xu J. PMID: 42834033 [PubMed - indexed for MEDLINE]
	Development of a Multimodal AI Model to Predict the Efficacy of Photodynamic Therapy for Local Residual or Recurrent Lesions Following Chemoradiotherapy or Radiotherapy for Esophageal Cancer. Dig Endosc Nakajo K, Sasagawa Y, Tomino T, Hirose H, Imai A, Endo M, Yamashita H, Yamamoto M, Takemura H, Yano T. PMID: 42833664 [PubMed - indexed for MEDLINE]
	The prognostic impact of sarcopenia and hypoalbuminemia on overall survival in esophageal cancer: a retrospective single-center study. Oncology Votavova K, Lohynska R, Drbohlavova T, Pala M, Rybkova M, Pechacova Z. PMID: 42832482 [PubMed - as supplied by publisher]

Articles 1 - 20 / 39818

Page 1 de 1991



		Intervalle de temps demandé

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy \| Publicité